Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Chronic heart failure Clinical criteria: Patient must be symptomatic with NYHA classes II or III, AND Patient must be in sinus rhythm, AND Patient must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%, AND Patient must have a resting heart rate at or above 77 bpm at the time ivabradine treatment is initiated, AND Patient must receive concomitant optimal standard chronic heart failure treatment, which must include the maximum tolerated dose of a beta-blocker, unless contraindicated or not tolerated. Resting heart rate should be measured by ECG or echocardiography, after 5 minutes rest. The ECG or echocardiography, result must be documented in the patient's medical records when treatment is initiated.
“Ivabradine is a heart rate lowering agent, acting by selective inhibition of the cardiac pacemaker If current that controls the spontaneous diastolic depolarisation in the sinus node and regulates heart rate.”
“6 hours”
“Ivabradine is extensively metabolised by the liver and the gut by oxidation through cytochrome P4503A4 (CYP3A4) only. Ivabradine has low affinity for CYP3A4, shows no clinically relevant CYP3A4 induction or inhibition and is therefore unlikely to modify CYP3A4 substrate metabolism or plasma concentrations.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.